Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis
Open Access
- 3 November 2020
- journal article
- research article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 60 (1) , 87-94
Abstract
Interstitial lung disease (ILD) represents one of the most severe extra-muscular features of idiopathic inflammatory myositis (IIM). We aimed to identify any clinical and serological predictors of ILD in a monocentric cohort of 165 IIM patients.ILD+ patients were defined as having restrictive impairment in lung function tests and signs of ILD at chest high-resolution computed tomography (HRCT). Available HRCT images were centralized and classified in different ILD patterns: non-specific interstitial pneumonia (NSIP), organizing pneumonia (OP), usual interstitial pneumonia-like (UIP), indeterminate for UIP, and interstitial lung abnormalities (ILA). Lung function test data were recorded at onset, at 1 and 5 years after ILD diagnosis.ILD was found in 52 IIM patients (31.5%): 46.2% was affected by anti-synthetase syndrome (ARS), 21% by polymyositis (PM), 19% by dermatomyositis (DM), and 13.5% by overlap myositis. Most of ILD+ showed NSIP (31.9%), OP (19%), indeterminate for UIP (19%), and UIP (12.8%) patterns. At multivariate analysis, ILD was predicted by anti-Ro52 (p: 0.0026) and dyspnea (p: 0.015) at IIM onset. Most of ILD onset within is 12 months after IIM. In five cases, ILD occurs after 12 months since IIM diagnosis: these patients more frequently show dry cough and anti-Ku antibodies. Anti-Ro52 + ILD patients showed a significant increase of DLCO at 1 and 5 years of follow-up, compared with anti-Ro52 negative cases.ILD occurs in about one third of IIM and was predicted by dyspnea at onset and anti-Ro52 antibodies. Anti-Ro52 defines a subgroup of ILD showing a significant improvement of DLCO during follow-up. This retrospective study has been approved by local ethic committee (ASST-Spedali Civili of Brescia, Italy); protocol number: NP3511Keywords
Funding Information
- Università degli Studi di Brescia
This publication has 45 references indexed in Scilit:
- Inclusion Body MyositisSeminars in Neurology, 2012
- KL‐6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositisJournal of Internal Medicine, 2011
- RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung diseaseArthritis & Rheumatism, 2009
- Interstitial lung disease guidelineThorax, 2008
- Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositisRespiratory Medicine, 2007
- Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathiesArthritis & Rheumatism, 2007
- In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung diseaseAutoimmunity, 2006
- Antisynthetase syndromeJoint Bone Spine, 2003
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975